Literature DB >> 27810091

Primary fascial closure with biologic mesh reinforcement results in lesser complication and recurrence rates than bridged biologic mesh repair for abdominal wall reconstruction: A propensity score analysis.

Salvatore Giordano1, Patrick B Garvey1, Donald P Baumann1, Jun Liu1, Charles E Butler2.   

Abstract

BACKGROUND: Previous studies suggest that bridged mesh repair for abdominal wall reconstruction may result in worse outcomes than mesh-reinforced, primary fascial closure, particularly when acellular dermal matrix is used. We compared our outcomes of bridged versus reinforced repair using ADM in abdominal wall reconstruction procedures.
METHODS: This retrospective study included 535 consecutive patients at our cancer center who underwent abdominal wall reconstruction either for an incisional hernia or for abdominal wall defects left after excision of malignancies involving the abdominal wall with underlay mesh. A total of 484 (90%) patients underwent mesh-reinforced abdominal wall reconstruction and 51 (10%) underwent bridged repair abdominal wall reconstruction. Acellular dermal matrix was used, respectively, in 98% of bridged and 96% of reinforced repairs. We compared outcomes between these 2 groups using propensity score analysis for risk-adjustment in multivariate analysis and for 1-to-1 matching.
RESULTS: Bridged repairs had a greater hernia recurrence rate (33.3% vs 6.2%, P < .001), a greater overall complication rate (59% vs 30%, P = .001), and worse freedom from hernia recurrence (log-rank P <.001) than reinforced repairs. Bridged repairs also had a greater rate of wound dehiscence (26% vs 14%, P = .034) and mesh exposure (10% vs 1%, P = .003) than mesh-reinforced abdominal wall reconstruction. When the treatment method was adjusted for propensity score in the propensity-score-matched pairs (n = 100), we found that the rates of hernia recurrence (32% vs 6%, P = .002), overall complications (32% vs 6%, P = .002), and freedom from hernia recurrence (68% vs 32%, P = .001) rates were worse after bridged repair. We did not observe differences in wound healing and mesh complications between the 2 groups.
CONCLUSION: In our population of primarily cancer patients at MD Anderson Cancer Center bridged repair for abdominal wall reconstruction is associated with worse outcomes than mesh-reinforced abdominal wall reconstruction. Particularly when employing acellular dermal matrix, reinforced repairs should be used for abdominal wall reconstruction whenever possible.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27810091     DOI: 10.1016/j.surg.2016.08.009

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  9 in total

1.  Preoperative Botulinum toxin A enabling defect closure and laparoscopic repair of complex ventral hernia.

Authors:  Omar Rodriguez-Acevedo; Kristen E Elstner; Anita S W Jacombs; John W Read; Rodrigo Tomazini Martins; Fernando Arduini; Michael Wehrhahm; Colette Craft; Peter H Cosman; Anthony N Dardano; Nabeel Ibrahim
Journal:  Surg Endosc       Date:  2017-07-21       Impact factor: 4.584

2.  Linear versus volumetric CT analysis in predicting tension-free fascial closure in abdominal wall reconstruction.

Authors:  M R Al-Mansour; J Wu; G Gagnon; A Knee; J R Romanelli; N E Seymour
Journal:  Hernia       Date:  2021-01-03       Impact factor: 4.739

3.  The Association of Coloproctology of Great Britain and Ireland consensus guidelines in emergency colorectal surgery.

Authors:  Andrew S Miller; Kathryn Boyce; Benjamin Box; Matthew D Clarke; Sarah E Duff; Niamh M Foley; Richard J Guy; Lisa H Massey; George Ramsay; Dominic A J Slade; James A Stephenson; Phil J Tozer; Danette Wright
Journal:  Colorectal Dis       Date:  2021-02       Impact factor: 3.917

4.  Multidisciplinary management of adult cloacal exstrophy complications: A challenging case of nephrolithiasis and abdominal wall extrusion of a catheterizable ileal pouch.

Authors:  Sarah S Christianson; Eric Ghiraldi; Justin Friedlander; Sameer Patel; Alfred Trang; Jay Simhan
Journal:  Urol Case Rep       Date:  2020-05-19

Review 5.  Systematic review of the stage of innovation of biological mesh for complex or contaminated abdominal wall closure.

Authors:  S K Kamarajah; S J Chapman; J Glasbey; D Morton; N Smart; T Pinkney; A Bhangu
Journal:  BJS Open       Date:  2018-06-14

6.  Long-term outcomes after contaminated complex abdominal wall reconstruction.

Authors:  F E E de Vries; J D Hodgkinson; J J M Claessen; O van Ruler; C A Leo; Y Maeda; O Lapid; M C Obdeijn; P J Tanis; W A Bemelman; J Constantinides; G B Hanna; J Warusavitarne; C Vaizey; M A Boermeester
Journal:  Hernia       Date:  2020-02-20       Impact factor: 4.739

7.  A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).

Authors:  William W Hope; Adel G El-Ghazzawy; Brad A Winterstein; Jeffrey A Blatnik; S Scott Davis; Jacob A Greenberg; Noel C Sanchez; Eric M Pauli; Daniel M Tseng; Karl A LeBlanc; Kurt E Roberts; Curtis E Bower; Eduardo Parra-Davila; J Scott Roth; Corey R Deeken; Eric F Smith
Journal:  Ann Med Surg (Lond)       Date:  2021-12-06

8.  Squid Ring Teeth-coated Mesh Improves Abdominal Wall Repair.

Authors:  Ashley N Leberfinger; Monika Hospodiuk; Abdon Pena-Francesch; Bugra Ayan; Veli Ozbolat; Srinivas V Koduru; Ibrahim T Ozbolat; Melik C Demirel; Dino J Ravnic
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-08-07

Review 9.  What is the evidence for the use of biologic or biosynthetic meshes in abdominal wall reconstruction?

Authors:  F Köckerling; N N Alam; S A Antoniou; I R Daniels; F Famiglietti; R H Fortelny; M M Heiss; F Kallinowski; I Kyle-Leinhase; F Mayer; M Miserez; A Montgomery; S Morales-Conde; F Muysoms; S K Narang; A Petter-Puchner; W Reinpold; H Scheuerlein; M Smietanski; B Stechemesser; C Strey; G Woeste; N J Smart
Journal:  Hernia       Date:  2018-01-31       Impact factor: 4.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.